(-0.02%) 5 477.25 points
(-0.04%) 38 803 points
(0.02%) 19 925 points
(0.29%) $80.56
(1.11%) $2.82
(0.12%) $2 331.70
(-0.36%) $29.29
(-0.13%) $969.60
(0.02%) $0.932
(-0.13%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...
Stats | |
---|---|
Šios dienos apimtis | 1.97M |
Vidutinė apimtis | 1.49M |
Rinkos kapitalizacija | 239.40M |
EPS | $-0.200 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.130 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.280 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.11 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
Tūris Koreliacija
Adaptimmune Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
NESRW | 0.929 |
BUJA | 0.921 |
AITR | 0.921 |
AAIDX | 0.915 |
SENEB | 0.914 |
RENE | 0.907 |
ANSC | 0.896 |
JAJWX | 0.894 |
ATMV | 0.892 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RDZN | -0.939 |
BTCT | -0.932 |
RENB | -0.929 |
PAX | -0.927 |
ICUCW | -0.926 |
INDV | -0.926 |
IBAC | -0.923 |
AIXI | -0.922 |
CHNR | -0.905 |
KITT | -0.904 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Adaptimmune Therapeutics Koreliacija - Valiuta/Žaliavos
Adaptimmune Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $60.51M |
Bruto pelnas: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2023 |
Pajamos: | $60.51M |
Bruto pelnas: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2022 |
Pajamos: | $27.15M |
Bruto pelnas: | $-100.58M (-370.48 %) |
EPS: | $-1.030 |
FY | 2021 |
Pajamos: | $6.15M |
Bruto pelnas: | $6.15M (100.00 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.